• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections
 


New Search Back to Search Results
 
Trade NameTHERASCREEN KRAS RGQ PCR KIT
Classification Namesomatic gene mutation detection system
ApplicantQIAGEN MANCHESTER LTD
PMA NumberP110027
Date Received07/25/2011
Decision Date05/23/2014
Product Code
OWD[ Registered Establishments with OWD ]
Docket Number 14M-0726
Notice Date 06/10/2014
Advisory Committee Pathology
Clinical Trials NCT00339183
NCT00364013
Expedited Review Granted? No
Combination Product Yes
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the therascreen kras rgq pcr kit, which is to be used as a companion diagnostic for the drug vectibix (panitumumab). This device is indicated for: the therascreen kras rgq pcr kit is a real-time qualitative pcr assay used on the rotor-gene q mdx instrument for the detection of seven somatic mutations in the human kras oncogene, using dna extracted from formalin-fixed paraffin-embedded (ffpe), colorectal cancer (crc) tissue. The therascreen kras rgq pcr kit is intended to aid in the identification of crc patients for treatment with erbitux (cetuximab) and vectibix (panitumumab) based on a kras no mutation detected test result.
Approval Order Approval Order
-
-